Neuraminidase has been considered as an important target for designing agents against influenza viruses. In a discovery of anti-influenza agents with epigoitrin as the initial lead compound, a series of 1-amino-2-alkanols were synthesized and biologically evaluated. The in vitro evaluation indicated that (E)-1-amino-4-phenylbut-3-en-2-ol (C1) had better inhibitory activities than 2-amino-1-arylethan-1-ol derivatives. To our surprise, sulfonation of C1 with 4-methoxybenzenesulfonyl chloride afforded more active inhibitor II with up to 6.4 μM IC₅₀ value against neuraminidase. Furthermore, docking of inhibitor II into the active site of NA found that the H atoms in both NH₂ and OH groups of inhibitor II were the key factors for potency. Molecular docking research did not explained very well the observed structure-activity relationship (SAR) from amino acid residue level, but also aided the discovery of (E)-1-amino-4-phenylbut-3-en-2-ol derivatives as novel and potent NA inhibitors.

神经氨酸酶已被认为是设计针对流感病毒的试剂的重要靶标。在发现以表铁蛋白为初始前导化合物的抗流感药时，合成了一系列的1-氨基-2-链烷醇并对其进行了生物学评估。在体外评价表明，（E）-1-氨基-4-苯基丁-3-烯-2-醇（C1）具有更好的抑制活性比2-氨基-1- arylethan -1-醇衍生物。令我们惊讶的是，用4-甲氧基苯磺酰氯磺化C1可得到更具活性的抑制剂II，其抗神经氨酸酶的IC ₅₀值高达6.4μM。此外，将抑制剂II插入NA的活性位点后发现，两个NH中的H原子抑制剂II的₂和OH基团是影响效力的关键因素。分子对接研究不能从氨基酸残基水平很好地解释观察到的结构-活性关系（SAR），但也有助于发现（E）-1-氨基-4-苯基丁-3-烯-2-醇衍生物，如新型有效的NA抑制剂。